Management of Transformed Chronic myeloid leukaemia: Ponatinib and Intensive chemotherapy: a dose finding trial
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 10 Jan 2019
Price : $35 *
At a glance
- Drugs Ponatinib (Primary) ; Antineoplastics
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- Acronyms MATCHPOINT
- 09 Oct 2018 Planned End Date changed from 15 Sep 2017 to 26 Apr 2021.
- 09 Oct 2018 Status changed from completed to active, no longer recruiting.
- 16 Sep 2017 Status changed from active, no longer recruiting to completed.